Cargando…
Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A)
OBJECTIVE: Current studies of newborn screening for Fabry disease in Taiwan have revealed a remarkably high prevalence of cardiac-type Fabry disease with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A). DESIGN: Retrospective cohort study. SETTING: Tertiary medical centre. PARTICIPANTS:...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717460/ https://www.ncbi.nlm.nih.gov/pubmed/23864212 http://dx.doi.org/10.1136/bmjopen-2013-003146 |
_version_ | 1782277695951863808 |
---|---|
author | Lin, Hsiang-Yu Liu, Hao-Chuan Huang, Yu-Hsiu Liao, Hsuan-Chieh Hsu, Ting-Rong Shen, Chia-I Li, Shao-Tzu Li, Cheng-Fang Lee, Li-Hong Lee, Pi-Chang Huang, Chun-Kai Chiang, Chuan-Chi Lin, Ching-Yuang Lin, Shuan-Pei Niu, Dau-Ming |
author_facet | Lin, Hsiang-Yu Liu, Hao-Chuan Huang, Yu-Hsiu Liao, Hsuan-Chieh Hsu, Ting-Rong Shen, Chia-I Li, Shao-Tzu Li, Cheng-Fang Lee, Li-Hong Lee, Pi-Chang Huang, Chun-Kai Chiang, Chuan-Chi Lin, Ching-Yuang Lin, Shuan-Pei Niu, Dau-Ming |
author_sort | Lin, Hsiang-Yu |
collection | PubMed |
description | OBJECTIVE: Current studies of newborn screening for Fabry disease in Taiwan have revealed a remarkably high prevalence of cardiac-type Fabry disease with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A). DESIGN: Retrospective cohort study. SETTING: Tertiary medical centre. PARTICIPANTS: 21 patients with cardiac-type Fabry disease (15 men and 6 women) as well as 15 patients with classic Fabry disease (4 men and 11 women) treated with biweekly intravenous infusions of agalsidase β (1 mg/kg) or agalsidase α (0.2 mg/kg) for at least 6 months. OUTCOME MEASURES: These data were collected at the time before enzyme replacement therapy (ERT) began and followed up after ERT for at least 6 months, including patient demographics, medical history, parameter changes of cardiac status and renal functions, plasma globotriaosylsphingosine (lyso-Gb3) and Mainz Severity Score Index. RESULTS: After 6–39 months of ERT, plasma lyso-Gb3 was found to be reduced in 89% (17/19) and 93% (14/15) of patients with cardiac-type and classic Fabry disease, respectively, which indicated an improvement of disease severity. For patients with cardiac-type Fabry disease, echocardiography revealed the reduction or stabilisation of left ventricular mass index (LVMI), the thicknesses of intraventricular septum (IVS) and left posterior wall (LPW) in 83% (15/18), 83% (15/18) and 67% (12/18) of patients, respectively, as well as 77% (10/13), 73% (11/15) and 60% (9/15) for those with classic type. Most patients showed stable renal function after ERT. There were statistically significant improvements (p<0.05) between the data at baseline and those after ERT for values of plasma lyso-Gb3, LVMI, IVS, LPW and Mainz Severity Score Index. No severe clinical events were reported during the treatment. CONCLUSIONS: ERT is beneficial and appears to be safe for Taiwanese patients with cardiac-type Fabry disease, as well as for those with the classic type. |
format | Online Article Text |
id | pubmed-3717460 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-37174602013-07-22 Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A) Lin, Hsiang-Yu Liu, Hao-Chuan Huang, Yu-Hsiu Liao, Hsuan-Chieh Hsu, Ting-Rong Shen, Chia-I Li, Shao-Tzu Li, Cheng-Fang Lee, Li-Hong Lee, Pi-Chang Huang, Chun-Kai Chiang, Chuan-Chi Lin, Ching-Yuang Lin, Shuan-Pei Niu, Dau-Ming BMJ Open Pharmacology and Therapeutics OBJECTIVE: Current studies of newborn screening for Fabry disease in Taiwan have revealed a remarkably high prevalence of cardiac-type Fabry disease with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A). DESIGN: Retrospective cohort study. SETTING: Tertiary medical centre. PARTICIPANTS: 21 patients with cardiac-type Fabry disease (15 men and 6 women) as well as 15 patients with classic Fabry disease (4 men and 11 women) treated with biweekly intravenous infusions of agalsidase β (1 mg/kg) or agalsidase α (0.2 mg/kg) for at least 6 months. OUTCOME MEASURES: These data were collected at the time before enzyme replacement therapy (ERT) began and followed up after ERT for at least 6 months, including patient demographics, medical history, parameter changes of cardiac status and renal functions, plasma globotriaosylsphingosine (lyso-Gb3) and Mainz Severity Score Index. RESULTS: After 6–39 months of ERT, plasma lyso-Gb3 was found to be reduced in 89% (17/19) and 93% (14/15) of patients with cardiac-type and classic Fabry disease, respectively, which indicated an improvement of disease severity. For patients with cardiac-type Fabry disease, echocardiography revealed the reduction or stabilisation of left ventricular mass index (LVMI), the thicknesses of intraventricular septum (IVS) and left posterior wall (LPW) in 83% (15/18), 83% (15/18) and 67% (12/18) of patients, respectively, as well as 77% (10/13), 73% (11/15) and 60% (9/15) for those with classic type. Most patients showed stable renal function after ERT. There were statistically significant improvements (p<0.05) between the data at baseline and those after ERT for values of plasma lyso-Gb3, LVMI, IVS, LPW and Mainz Severity Score Index. No severe clinical events were reported during the treatment. CONCLUSIONS: ERT is beneficial and appears to be safe for Taiwanese patients with cardiac-type Fabry disease, as well as for those with the classic type. BMJ Publishing Group 2013-07-16 /pmc/articles/PMC3717460/ /pubmed/23864212 http://dx.doi.org/10.1136/bmjopen-2013-003146 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Pharmacology and Therapeutics Lin, Hsiang-Yu Liu, Hao-Chuan Huang, Yu-Hsiu Liao, Hsuan-Chieh Hsu, Ting-Rong Shen, Chia-I Li, Shao-Tzu Li, Cheng-Fang Lee, Li-Hong Lee, Pi-Chang Huang, Chun-Kai Chiang, Chuan-Chi Lin, Ching-Yuang Lin, Shuan-Pei Niu, Dau-Ming Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A) |
title | Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A) |
title_full | Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A) |
title_fullStr | Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A) |
title_full_unstemmed | Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A) |
title_short | Effects of enzyme replacement therapy for cardiac-type Fabry patients with a Chinese hotspot late-onset Fabry mutation (IVS4+919G>A) |
title_sort | effects of enzyme replacement therapy for cardiac-type fabry patients with a chinese hotspot late-onset fabry mutation (ivs4+919g>a) |
topic | Pharmacology and Therapeutics |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717460/ https://www.ncbi.nlm.nih.gov/pubmed/23864212 http://dx.doi.org/10.1136/bmjopen-2013-003146 |
work_keys_str_mv | AT linhsiangyu effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga AT liuhaochuan effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga AT huangyuhsiu effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga AT liaohsuanchieh effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga AT hsutingrong effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga AT shenchiai effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga AT lishaotzu effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga AT lichengfang effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga AT leelihong effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga AT leepichang effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga AT huangchunkai effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga AT chiangchuanchi effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga AT linchingyuang effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga AT linshuanpei effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga AT niudauming effectsofenzymereplacementtherapyforcardiactypefabrypatientswithachinesehotspotlateonsetfabrymutationivs4919ga |